Last10K.com

Anixa Biosciences Inc (ANIX) SEC Filing 10-Q Quarterly report for the period ending Tuesday, April 30, 2019

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX
Document And Entity Information - shares
6 Months Ended
Apr. 30, 2019
Jun. 11, 2019
Document and Entity Information [Abstract]  
Entity Registrant NameAnixa Biosciences Inc 
Document Type10-Q 
Current Fiscal Year End Date--10-31 
Entity Common Stock, Shares Outstanding 20,096,743
Amendment Flagfalse 
Entity Central Index Key0000715446 
Entity Current Reporting StatusYes 
Entity Filer CategoryNon-accelerated Filer 
Document Period End DateApr. 30, 2019 
Document Fiscal Year Focus2019 
Document Fiscal Period FocusQ2 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Ex Transition Periodfalse 

View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.

Continue

Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
Legal
Other
Filter by Subcategory:
All
Earnings
Product
Expense
Cash Flow
Income
Shares
Other
Inside Anixa Biosciences Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parentheticals)
Condensed Consolidated Statement Of Shareholder`S Equity (Unaudited)
Condensed Consolidated Statement Of Shareholder`S Equity (Unaudited) (Parentheticals)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited) (Parentheticals)
Accrued Expenses
Accrued Expenses (Details) - Accrued Liabilities
Accrued Expenses (Tables)
Business And Funding
Business And Funding (Details)
Business And Funding (Details) - Changes In Noncontrolling Interest
Business And Funding (Details) - Patents
Business And Funding (Tables)
Commitment And Contingences
Effect Of Recently Adopted And Issued Pronouncements
Fair Value Measurements
Fair Value Measurements (Details) - Hierarchy For Financial Assets Measured At Fair Value
Fair Value Measurements (Tables)
Income Taxes
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Details)
Segment Information
Segment Information (Details)
Segment Information (Details) - Segments Information
Segment Information (Tables)
Stock Based Compensation
Stock Based Compensation (Details) - Employee Stock Purchase Plan
Stock Based Compensation (Details) - Information Regarding Stock Options Outstanding That Were Not Granted Under The 2003 Share Plan, The 2010 Share Plan Or The 2018 Share Plan
Stock Based Compensation (Details) - Information Regarding The 2003 Share Plan
Stock Based Compensation (Details) - Information Regarding The 2010 Share Plan
Stock Based Compensation (Details) - Information Regarding The 2018 Share Plan
Stock Based Compensation (Details) - Stock Awards
Stock Based Compensation (Details) - Stock Option Activity
Stock Based Compensation (Details) - Stock Option Compensation Expense
Stock Based Compensation (Details) - Stock Option Plans
Stock Based Compensation (Details) - Stock Options Outstanding And Exercisable That Were Not Granted Under The 2003 Share Plan, The 2010 Share Plan Or The 2018 Plan
Stock Based Compensation (Details) - Stock Options Outstanding And Exercisable Under The 2003 Share Plan
Stock Based Compensation (Details) - Stock Options Outstanding And Exercisable Under The 2010 Share Plan
Stock Based Compensation (Details) - Stock Options Outstanding And Exercisable Under The 2018 Share Plan
Stock Based Compensation (Details) - Warrants
Stock Based Compensation (Tables)

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001513162-19-000156
Submitted to the SEC: Tue Jun 11 2019 1:51:38 PM EST
Accepted by the SEC: Wed Jun 12 2019
Period: Tuesday, April 30, 2019
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/anix/0001513162-19-000156.htm